Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04566328 · ClinicalTrials.gov registry record · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
A Phase 3 study of Plasma Cell Myeloma and RISS Stage I Plasma Cell Myeloma, sponsored by ECOG-ACRIN Cancer Research Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,450
- Enrollment target
- 20
- Study locations
NCT04566328 is a Phase 3 study of Plasma Cell Myeloma and RISS Stage I Plasma Cell Myeloma that is actively recruiting participants, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,450 participants, above the 163-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (790% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04566328, a Phase 3 study of Plasma Cell Myeloma and RISS Stage I Plasma Cell Myeloma, is actively recruiting participants, sponsored by ECOG-ACRIN Cancer Research Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,450 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bortezomib
- BIOLOGICAL Daratumumab and Hyaluronidase-fihj
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Cancer Center at Saint Joseph's - Phoenix
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- CARTI Cancer Center - Little Rock
- John L McClellan Memorial Veterans Hospital - Little Rock
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- Sutter Auburn Faith Hospital - Auburn
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,450 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04566328
The ClinicalTrials.gov registry entry for NCT04566328 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 163-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (790% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04566328 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04566328 about?
NCT04566328 is a clinical study titled "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial". This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell g...
What is the current status of trial NCT04566328?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,450 participants. The study started on 2021-02-24. Estimated completion is 2027-12-31.
What conditions does trial NCT04566328 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma.
What interventions are being tested in trial NCT04566328?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Dexamethasone (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG), Daratumumab and Hyaluronidase-fihj (BIOLOGICAL).
Who is sponsoring clinical trial NCT04566328?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04566328 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RECRUITING · Phase 3
-
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 3
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.